ProCE Banner Activity

Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT

Slideset Download
Conference Coverage
In this retrospective analysis of CIBMTR-collected blood samples, NGS-MRD detection of NPM1 mutations and/or FLT3-ITD was associated with significant prognostic value for relapse and survival in patients with AML in first remission prior to allogeneic HCT.

Released: June 17, 2022

Expiration: June 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab